Surgical interventions in a cohort of patients with haemophilia A and inhibitors: An experiential retrospective chart review

Haemophilia

Volumn 13, Issue 5, 2007, Pages 508-517

  Kraut, Erik H ^a   Aledort, L M ^b   Arkin, S ^c   Stine, K C ^d   Wong, W Y ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Anti inhibitor Coagulant Complex; Bypassing agents; Factor Eight Inhibitor Bypassing Activity; Haemophilia; Inhibitors; Recombinant factor VIIa; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY TITER; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG USE; HEMOPHILIA A; HEMOSTASIS; HUMAN; MEDICAL RECORD REVIEW; MONOTHERAPY; PATIENT CARE; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SURGICAL PATIENT; SURGICAL TECHNIQUE; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FACTOR VII; FEMALE; HEMOPHILIA A; HUMANS; INFANT; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34548297571     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01523.x     Document Type: Review

References (30)

1. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10 (Suppl. 2): 41-5.
2. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10 (Suppl. 2): 22-9.
3. Rodriguez-Merchan EC, Rocino A, Ewenstein B et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: Summary statement. Haemophilia 2004; 10 (Suppl. 2): 50-2.
4. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities. Semin Hematol 2004; 41 (Suppl. 1): 109-16.
5. Kulkarni R, Aledort LM, Berntorp E et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001; 67: 240-6.
6. MASAC. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation. MASAC Recommendations Regarding Radionuclide Synovectomy (document 176), adopted on October, 15 2006. National Hemophilia Foundation website. Available at http://www.hemophilia.org/ NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=692, accessed on 22 March 2007.
7. Dunn AL, Busch MT, Wyly JB, Abshire TC. Radionuclide synovectomy for hemophilic arthropathy: A comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. Thromb Haemost 2002; 87: 383-93.
8. Berntorp E. Options for treating acute bleeds in addition to bypassing agents: Extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics. Haemophilia 2006; 12 (Suppl. 6): 62-6.
9. Hvid I, Rodriguez-Merchan EC. Orthopaedic surgery in haemophilic patients with inhibitors: An overview. Haemophilia 2002; 8: 288-91.
10. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
11. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004; 10 (Suppl. 2): 30-40.
12. Goddard N. Case studies: Orthopaedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia 2005; 11 (Suppl. 1): 32-7.
13. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
14. Dargaud Y, Meunier S, Negrier C. Haemophilia and thrombophilia: An unexpected association! Haemophilia 2004; 10: 319-26.
15. Pruthi RK, Heit JA, Green MM et al. Venous thromboembolism after hip fracture surgery in a patient with haemophilia B and factor V Arg506Gln (factor V Leiden). Haemophilia 2000; 6: 631-4.
16. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
17. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64.
18. Ludlam C. Identifying and managing inhibitor patients requiring orthopaedic surgery - the multidisciplinary team approach. Haemophilia 2005; 11 (Suppl. 1): 7-10.
19. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
20. Schneiderman J, Rubin E, Nugent D, Young G. Sequential rFVIIa and FEIBA for the management of bleeding episodes in inhibitor patients: Update of our previous report [abstract]. Haemophilia 2006; 12 (Suppl. 2): 57.
21. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors' Organisation. Br J Haematol 2006; 133: 591-605.
22. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia 1998; 4: 564-7.
23. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
24. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: Pathophysiology and treatment. Hematol Am Soc Hematol Educ Program 2006; January 2006: 432-7.
25. Teitel JM, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
26. FEIBA VH Anti-Inhibitor Coagulant Complex [Package Insert]. Vienna, Austria: Baxter Healthcare Corporation, 2005.
27. NovoSeven [Package Insert]. Princeton, NJ: Novo Nordisk A/S, 2006.
28. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
29. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol 2004; 41 (Suppl. 1): 125-31.
30. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I, Samama MM. Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 2005; 3: 16.